Literature DB >> 26601996

Audiologic evaluations of children with mucopolysaccharidosis.

Çağıl Gökdoğan1, Şenay Altinyay2, Ozan Gökdoğan3, Hakan Tutar4, Bülent Gündüz2, İlyas Okur5, Leyla Tümer6, Yusuf Kemal Kemaloğlu4.   

Abstract

INTRODUCTION: Mucopolysaccharidosis is a hereditary lysosomal storage disease, which develops due to a deficiency in the enzymes that play a role in the metabolism of glycosaminoglycans (GAG). The incidence of mucopolysaccharidosis is 1/25,000, with autosomal recessive inheritance (except for MPS II). Mucopolysaccharidosis occurs in seven different types, each with a different congenital deficiency of lysosomal enzymes. In mucopolysaccharidosis patients, even though progression of clinical findings is not prominent, the disease advances and causes death at early ages. Facial dysmorphism, growth retardation, mental retardation, and skeletal or joint dysplasia are the most frequently found symptoms in these patients.
OBJECTIVE: The purpose of our study is to present the types of hearing loss types and tympanometric findings of patients with mucopolysaccharidosis referred to our clinic with suspicion of hearing loss.
METHODS: After otorhinolaryngological examination, 9 patients with different types of mucopolysaccharidosis, underwent to immittance and audiometric evaluations, performed according to their physical and mental abilities, and ages, in order to determine their hearing thresholds.
RESULTS: The audiometric findings of the 9 patients followed with mucopolysaccharidosis were reported separately for each case.
CONCLUSION: Based on the high frequency of hearing loss in mucopolysaccharidosis patients, early and detailed audiological evaluations are highly desirable. Therefore, regular and systematic multidisciplinary evaluations are very important.
Copyright © 2015 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier Editora Ltda. All rights reserved.

Entities:  

Keywords:  Audiologic evaluation; Avaliação audiológica; Hearing loss; Mucopolissacaridose; Mucopolysaccharidosis; Perda auditiva

Mesh:

Year:  2015        PMID: 26601996      PMCID: PMC9444605          DOI: 10.1016/j.bjorl.2015.05.007

Source DB:  PubMed          Journal:  Braz J Otorhinolaryngol        ISSN: 1808-8686


Introduction

Mucopolysaccharidosis (MPS) is a hereditary lysosomal storage disease, which develops due to the deficiency in the enzymes that play a role in the metabolism of glycosaminoglycans (GAG). Progressive GAG accumulation causes advanced growth retardation, skeletal deformities, hearing loss, weak joint movement, and facial dysmorphism. In accordance with the deficiency of the known 11 enzymes, MPS has seven sub-types (MPS I, MPS II, MPS III, MPS IV, MPS VI, MPS VII, MPS IX). Although the incidence of MPS in accordance with its sub-types varies, a general incidence of 1/25,000 has been reported.1, 2, 3 In patients with MPS, hearing loss is observed due to various reasons. Conductive hearing loss (CHL) may develop due to recurrent upper respiratory tract infections and serous otitis media or bone chain deformities. Sensorineural hearing loss (SHL) is thought to be caused due to the accumulation of GAG in the cochlea, auditory nerve, and brain stem. In many patients, mixed-type hearing loss, along with the symptoms of conductive and sensorineural hearing loss, can also be seen. In CHL related to middle ear effusion, while the ventilation tube implementation is frequently used as treatment, hearing aids are advised in SHL.4, 5, 6, 7 Early diagnosis of hearing losses carries great importance in terms of early intervention in MPS patients, as well as in all other patients.8, 9 The purpose of the present study was to present the hearing loss type, degree, and tympanometric findings of patients with MPS, who are directed to this clinic with the suspicion of hearing loss.

Methods

The nine patients who had been directed to this department with the suspicion of hearing loss, whose follow-up had been conducted after they have been diagnosed with MPS, were included in this study (Ethical Committee approval number: GÜKAEK-461). The otological examinations of the patients were performed by the otorhinolaryngologist. Information related to each patient's otorhinolaryngological complaints and treatments were compiled and middle ear infection, ear discharge, tinnitus, dizziness, tympanum problems, adenoidectomy, ear tube placement, and hearing aid usage were determined. After the otorhinolaryngological examination, the immitancemetric evaluations were conducted and tests which are appropriate for the patients’ ages, physical and mental efficiencies, and both air and bone conduction thresholds were determined at 250, 500, 1000, 2000, 4000, 6000, and 8000 Hz. The hearing loss levels were determined by taking the average of pure tone air conduction thresholds, determined at 0.5, 1, 2, and 4 kHz, in accordance with the intervals given in Table 1.
Table 1

Degree of hearing loss (dB HL).

Degree of hearing lossHearing loss range (dB HL)
Normal−10 to 15
Slight16–25
Mild26–40
Moderate41–55
Moderately severe56–70
Severe71–90
Profound90+
Degree of hearing loss (dB HL). Hear loss was classified under three groups as conductive, mixed, and sensorineural. For CHL, while the bone hearing thresholds were present audiometrically (less than 20 dB), it has been accepted that; the average air-bone gap in 0.5, 1, 2 kHz to be more than 15 dB; in mixed type hearing losses, bone hearing thresholds to be 20 dB and over audiometrically and the average air-bone gap to be more than 15 dB in 0.5, 1, 2 kHz; in sensorineural hearing loss (SHL), the difference between the air and bone conduction thresholds to be less than 15 dB in average in 0.5, 1, 2 kHz. In the tympanometrical evaluation, 225 Hz probe tone signals were used. The tympanogram types were evaluated in accordance with the values given in Table 2.
Table 2

Tympanogram types (daPa).

Tympanogram typePressure intervals (daPa)
Type A+50 to (−150)
Type B−400
Type C−150 to (−399)
Tympanogram types (daPa).

Statistical analysis

For the statistical analysis, SPSS version 16.0 (SPSS Inc., Chicago, IL, United States) was used. For the age average and standard deviation (SD), descriptive statistics were developed.

Results

The age average of the total of nine patients with MPS, four female (44.44%) and five male (55.55%), was determined as 5.66 ± 2.73. There were three cases of MPS VI (33.33%), three cases of MPS I (33.33%), one case of MPS III (11.11%), and two cases of MPS IV (22.22%) that were diagnosed. Cases MÖ and EÖ are siblings; İK and İK 2 are twins. The other five patients are not related. The degree of hearing loss, its type, and tympanometrical findings are shown in Table 3. There were six ears with conductive hearing loss (33.33%) (HL one ear: slight; HL one ear: mild; HL two ears: moderate, and HL two ears: moderately severe); 12 ears with mixed hearing loss (66.66%) (HL two ears: mild; HL four ears: moderate, HL five ears: severe, and HL one ear: profound) were determined. There were 14 ears with Type B tympanogram (77.77%), three ears with Type C tympanogram (16.66%), and one ear with Type A tympanogram (5.55%). E.Ç., B.E.B., and MSE had a bilateral ventilation tube (VT) inserted. Although the other patients were advised regarding the VT application as well, it has not been carried out upon the wish of their families. With the exception of MÖ and BEB, although all patients were advised to use hearing aids, the families did not adopt the use of these devices and did not come regularly for follow-ups.
Table 3

Audiometrical findings of patients with MPS.

PatientAgeaDiagnosisTympanometrical findings
Type of hearing loss
Degree of hearing loss
RightLeftRightLeftRightLeft
9MPS VIType CType AConductiveConductiveSlightMild
4MPS VIType CType CMixedMixedModerateModerate
İK3MPS IType BType BMixedMixedSevereSevere
İK23MPS IType BType BMixedMixedSevereSevere
9MPS VIType BType BConductiveConductiveModerateModerately severe
SD8MPS IVType BType BMixedMixedModerateMild
BEB6MPS IType BType BConductiveConductiveModerateModerately severe
MSE7MPS IVType BType BMixedMixedModerateModerate
YCE2MPS IIIType BType BMixedMixedSevereProfound

In years.

Audiometrical findings of patients with MPS. In years.

Discussion

In cases with MPS (Table 4), the initiation of treatment in early stages carries great importance in terms of the prognosis of the disease. However, due to the late appearance of the symptoms, the definite diagnosis range is 3–4 years of age. In the follow-up of the stages of the treatments of patients with MPS, the otolaryngologist and audiologists have a significant role in multidisciplinary teamwork. Recurrent serous otitis media and hearing loss that develops in individuals within this disease group are the reasons why better, long-term follow-ups should be done. Hearing loss can be seen in various types and degrees in MPS in general.10, 11, 12, 13 Overall, conductive hearing losses due to chronic effusion and eustachian tube dysfunction are seen more in patients with MPS; the incidence of SHL has not been determined very clearly.
Table 4

Air and bone conduction thresholds of patients with MPS (dB HL).

PatientAverage air conduction thresholds (500–4000 Hz)
Average bone conduction thresholds (500–4000 Hz)
RightLeftRightLeft
22.526.256.256.25
6557.53030
İK70a35b
İK270a45b
46.256012.512.5
SD47.538.7518.7522.5
BEB51.2556.251515
MSE43.754518.7518.75
YCE81.259022.522.5

The air conduction thresholds have been determined in free field.

The bone conduction thresholds have been determined in accordance with the speech recognition thresholds.

Air and bone conduction thresholds of patients with MPS (dB HL). The air conduction thresholds have been determined in free field. The bone conduction thresholds have been determined in accordance with the speech recognition thresholds. Although conductive and mixed-type hearing loss were observed in the cases of the present study, SHL compatible with literature has not been determined. In the studies conducted, it was stated that the incidence of mixed hearing loss is more, and that this fact is related with age. While conductive hearing loss is determined in early ages and in patients who are diagnosed earlier, it has been stated that mixed hearing loss can be observed, and that this rate is between 33% and 71% as age increases. In the present cases, degree of hearing loss was determined from slight to severe. This difference is considered to be due to GAG's excessive accumulation in the cochlear ducts, stria vascularis, and cochlear nerve, which prevents them from functioning efficiently. In the present cases, the incidence of Type B and C tympanogram was determined to be high, in accordance with the literature. According to Yu Lin et al., while this rate is stated to reach 70%, the incidence of Type B tympanogram was determined as 77.77% and the incidence of Type C tympanogram was determined as 16.66% in the present study, similarly. VT application is advised to cases with similar clinical findings in different clinics as well, just as in the present study. However, a majority of the cases in this study have hindered their treatments, due to their families’ rejection of the VT application. In cases for which hearing aids are advised, while socio-economical inadequacy creates hardships in coming to follow-ups and obtaining these aids, the fact that many live in different cities prevents continuity in follow-ups.

Conclusion

In cases with MPS, since the incidence of hearing loss is high, the hearing loss should be determined in early stages. After the diagnosis, the required treatments should be started promptly and thus quality of life should be increased. However, it is considered that this is only possible as a result of regular and systematic follow-ups and with multidisciplinary studies.

Conflicts of interest

The authors declare no conflicts of interest.
  10 in total

Review 1.  Otorhinolaryngological manifestations of the mucopolysaccharidoses.

Authors:  M A Simmons; I A Bruce; S Penney; E Wraith; M P Rothera
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2005-05       Impact factor: 1.675

2.  Hearing loss in patients with mucopolysaccharidosis II: data from HOS - the Hunter Outcome Survey.

Authors:  Annerose Keilmann; Todsaporn Nakarat; Iain A Bruce; David Molter; Gunilla Malm
Journal:  J Inherit Metab Dis       Date:  2011-08-25       Impact factor: 4.982

3.  [Phoniatric aspects of children with mucopolysaccharidosis].

Authors:  E Schleier; H G Streubel
Journal:  Folia Phoniatr (Basel)       Date:  1976

4.  Otolaryngologic manifestations of the mucopolysaccharidoses.

Authors:  J K Bredenkamp; M E Smith; J P Dudley; J C Williams; R L Crumley; D M Crockett
Journal:  Ann Otol Rhinol Laryngol       Date:  1992-06       Impact factor: 1.547

5.  Hearing loss in Hunter's syndrome--mucopolysaccharidosis II.

Authors:  J E Peck
Journal:  Ear Hear       Date:  1984 Jul-Aug       Impact factor: 3.570

6.  Role of the pediatric otolaryngologist in diagnosis and management of children with mucopolysaccharidoses.

Authors:  Stephen M Wold; Craig S Derkay; David H Darrow; Virginia Proud
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2009-11-20       Impact factor: 1.675

Review 7.  Newborn screening and diagnosis of mucopolysaccharidoses.

Authors:  Shunji Tomatsu; Tadashi Fujii; Masaru Fukushi; Toshihiro Oguma; Tsutomu Shimada; Miho Maeda; Kazuhiro Kida; Yuniko Shibata; Hideyuki Futatsumori; Adriana M Montaño; Robert W Mason; Seiji Yamaguchi; Yasuyuki Suzuki; Tadao Orii
Journal:  Mol Genet Metab       Date:  2013-06-21       Impact factor: 4.797

8.  Airway management in mucopolysaccharide storage disorders.

Authors:  Shai Y Shinhar; Hedy Zablocki; David N Madgy
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2004-02

9.  Histopathological studies of the temporal bones in Hurler's disease [mucopolysaccharidosis (MPS) IH].

Authors:  I Friedmann; E Spellacy; J Crow; R W Watts
Journal:  J Laryngol Otol       Date:  1985-01       Impact factor: 1.469

Review 10.  Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA.

Authors:  Christian J Hendriksz; Maisoon Al-Jawad; Kenneth I Berger; Sara M Hawley; Rebecca Lawrence; Ciarán Mc Ardle; C Gail Summers; Elizabeth Wright; Elizabeth Braunlin
Journal:  J Inherit Metab Dis       Date:  2012-02-23       Impact factor: 4.982

  10 in total
  9 in total

Review 1.  Molecular genetics and metabolism, special edition: Diagnosis, diagnosis and prognosis of Mucopolysaccharidosis IVA.

Authors:  Hira Peracha; Kazuki Sawamoto; Lauren Averill; Heidi Kecskemethy; Mary Theroux; Mihir Thacker; Kyoko Nagao; Christian Pizarro; William Mackenzie; Hironori Kobayashi; Seiji Yamaguchi; Yasuyuki Suzuki; Kenji Orii; Tadao Orii; Toshiyuki Fukao; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2018-05-15       Impact factor: 4.797

Review 2.  ENT and mucopolysaccharidoses.

Authors:  Pier Marco Bianchi; Renato Gaini; Silvano Vitale
Journal:  Ital J Pediatr       Date:  2018-11-16       Impact factor: 2.638

3.  Audiometric evaluation in individuals with mucopolysaccharidosis.

Authors:  Marcela Rosana Maia da Silveira; Ana Karina Lima Buriti; Ana Maria Martins; Daniela Gil; Marisa Frasson de Azevedo
Journal:  Clinics (Sao Paulo)       Date:  2018-12-03       Impact factor: 2.365

4.  Hearing loss in patients with mucopolysaccharidoses-1 and -6 after hematopoietic cell transplantation: A longitudinal analysis.

Authors:  Brigitte T A van den Broek; Adriana L Smit; Jaap Jan Boelens; Peter M van Hasselt
Journal:  J Inherit Metab Dis       Date:  2020-07-09       Impact factor: 4.982

5.  Audiological and otologic manifestations of glutaric aciduria type I.

Authors:  Yen-Chi Chen; Chii-Yuan Huang; Yen-Ting Lee; Chia-Hung Wu; Sheng-Kai Chang; Hsiu-Lien Cheng; Po-Hsiung Chang; Dau-Ming Niu; Yen-Fu Cheng
Journal:  Orphanet J Rare Dis       Date:  2020-12-01       Impact factor: 4.123

6.  Neurophysiology of hearing in patients with mucopolysaccharidosis type IV.

Authors:  Kyoko Nagao; Thierry Morlet; Elizabeth Haley; Jennifer Padilla; Julianne Nemith; Robert W Mason; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2018-02-08       Impact factor: 4.204

7.  Hunter Syndrome Diagnosed by Otorhinolaryngologist.

Authors:  Ayako Hashimoto; Tadayuki Kumagai; Hiroyuki Mineta
Journal:  Case Rep Otolaryngol       Date:  2018-05-13

Review 8.  Hearing Loss in Mucopolysaccharidoses: Current Knowledge and Future Directions.

Authors:  Jeremy Wolfberg; Keerthana Chintalapati; Shunji Tomatsu; Kyoko Nagao
Journal:  Diagnostics (Basel)       Date:  2020-08-04

9.  Otorhinolaryngological Management in Taiwanese Patients with Mucopolysaccharidoses.

Authors:  Chung-Lin Lee; Kuo-Sheng Lee; Chih-Kuang Chuang; Chin-Hui Su; Huei-Ching Chiu; Ru-Yi Tu; Yun-Ting Lo; Ya-Hui Chang; Hsiang-Yu Lin; Shuan-Pei Lin
Journal:  Int J Med Sci       Date:  2021-07-25       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.